Search Results
SOLO-1: practice changing results for advanced ovarian cancer
SOLO-1: practice changing data on olaparib for ovarian cancer
Impact of SOLO-1 on Advanced Ovarian Cancer Management
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?
SOLO-1 and PARP Inhibitors in Ovarian Cancer
Practice-Changing Updates in Ovarian Cancer: Implications for Pathways Construction
SOLO1 trial of maintenance olaparib in advanced ovarian cancer | Susana Banerjee
Highly Anticipated Data from the SOLO-1 Trial
SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer
Ovarian news from ESMO 2018: SOLO-1 results for olaparib
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer